Cue Biopharma will discuss clinical updates and business strategies at the Piper Sandler Healthcare Conference on December 4, 2024.
Quiver AI Summary
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutic biologics for cancer and autoimmune diseases, has announced its participation in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference in New York, scheduled for December 3-5, 2024. The session will feature CEO Daniel Passeri, who will share updates on recent clinical and preclinical programs, as well as the company's strategic business objectives. The discussion is set for December 4, 2024, from 9:00 to 9:25 a.m. EST, and will be available via a live and archived webcast. Cue Biopharma utilizes its proprietary Immuno-STAT™ platform to selectively engage disease-specific T cells, aiming to leverage the body's immune system with reduced adverse effects. For more details, visit their website or follow them on social media.
Potential Positives
- Participation in a prominent conference (Piper Sandler 36th Annual Healthcare Conference) provides visibility and engagement opportunities with potential investors and partners.
- Presentation of recent clinical and preclinical program updates signals progress and transparency in the company’s development pipeline.
- Webcast availability allows for broad access to the company's strategic insights and developments, potentially attracting interest from a wider audience.
- The presence of an experienced management team and board enhances investor confidence in the company's capabilities and strategic direction.
Potential Negatives
- Company is identified as "clinical-stage," which may indicate a lack of commercially available products and potentially greater investment risk.
- Participation in the conference suggests a need to reassure investors about ongoing developments, potentially hinting at previous uncertainties in their clinical programs.
- No specific updates on clinical trial results or regulatory progress are provided, which may raise concerns among investors about the company's current performance and future prospects.
FAQ
What is Cue Biopharma's focus in biopharmaceuticals?
Cue Biopharma develops therapeutic biologics that selectively engage and modulate disease-specific T cells to treat cancer and autoimmune diseases.
When is Cue Biopharma's discussion at the Piper Sandler Conference?
The discussion will take place on December 4, 2024, from 9 a.m. to 9:25 a.m. EST.
How can I access the webcast of Cue Biopharma's presentation?
You can access the live and archived webcast at https://event.webcasts.com/starthere.jsp?ei=1697351&tp_key=a82c532edc.
What is Immuno-STAT™ technology?
Immuno-STAT™ is Cue Biopharma's proprietary platform designed for the selective targeting and modulation of T cells within the patient’s body.
Where is Cue Biopharma headquartered?
Cue Biopharma is headquartered in Boston, Massachusetts.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CUE Hedge Fund Activity
We have seen 11 institutional investors add shares of $CUE stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLEICHROEDER LP added 2,135,634 shares (+74.6%) to their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC removed 274,033 shares (-100.0%) from their portfolio in Q2 2024
- MONACO ASSET MANAGEMENT SAM removed 253,185 shares (-100.0%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 247,810 shares (-93.0%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP removed 212,105 shares (-60.5%) from their portfolio in Q3 2024
- DIMENSIONAL FUND ADVISORS LP removed 199,514 shares (-93.2%) from their portfolio in Q3 2024
- BLACKROCK, INC. removed 185,761 shares (-24.5%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.
Presentation Details
Date and Time:
Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST
Webcast Link:
https://event.webcasts.com/starthere.jsp?ei=1697351&tp_key=a82c532edc
Presenter:
Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company’s website at www.cuebiopharma.com . The webcast will be archived for 30 days.
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™
(Selective Targeting and Alteration of T cells)
, and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn .
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
[email protected]
Media Contact
Jonathan Pappas
LifeSci Communications
[email protected]
